Validation of novel CAR-T cell therapies against colorectal cancer
Files
(Library staff access only.)
Date
2023
Authors
Rohani Rad, Elaheh
Editors
Advisors
McColl, Shaun
Comerford, Iain
Comerford, Iain
Journal Title
Journal ISSN
Volume Title
Type:
Thesis
Citation
Statement of Responsibility
Conference Name
Abstract
Chimeric antigen receptor (CAR) T cell therapy has demonstrated a high degree of efficacy in patients with haematological malignancies such as acute lymphatic leukaemia. However, its efficacy in solid tumours remains to be demonstrated. There are a number of issues currently limiting therapeutic treatment of solid tumours with CAR-T cells, none more important than target antigen selection. This is a major challenge in solid tumours due to their heterogenous characteristics and potential off-cancer effects. ADAM10, A Disintegrin And Metalloproteinase 10, plays critical roles in a wide range of pathophysiological processes during development and inflammation. These proteolytically active multifunctional proteins act as sheddase by cleaving transmembrane-bound proteins such as growth factors, adhesion molecules and chemokine receptors, which can then contribute to migration and invasion of cancer cells. An active form of ADAM10 that has undergone a conformational change has been identified in several cancer types, particularly colorectal cancer. In this study, a novel CAR was generated based on a previously characterised conformation cancer-specific ADAM10 antibody. Another potential target for CAR-T therapy is leucine-rich repeat-containing G-protein coupled receptor (LGR5), which is a cancer stem cell marker and plays a significant role in the initiation and spreading of tumours. The research in this thesis examines the hypothesis that CAR-T cells directed against ADAM10 and LGR5 will kill colorectal cancer cells and inhibit growth of colorectal tumours in preclinical models. To test this hypothesis, both ADAM-10 and LGR5-targeting CAR-T cells were manufactured using T cells from the peripheral blood of the healthy donors. These CAR-T cells displayed the naïve and central memory phenotype that has been shown to differentiate and proliferate within tumour microenvironments, with little expression of exhaustion markers. These CAR-T cells were capable of killing several human colorectal tumour cell lines in vitro, assessed in a bioluminescence-based cytotoxicity assay. Furthermore, treatment of NSG mice bearing human LoVo colon cancer cell tumours with both ADAM-10 and LGR5-targeting CAR-T cells led to significant inhibition of tumour growth compared with either untransduced control T cells or PBS treatment. These data indicate that targeting ADAM-10 and LGR5 via CAR-T cell therapy is a promising novel avenue of treatment of colorectal cancer. The study also explored engineering the expression of chemokine receptors, with CXCR2 expression resulting in enhanced in vivo anti-tumour efficacy of LGR5-targeting CAR-T cells, but without impacting the efficacy of CXCR2 modified ADAM10-targeting CAR-T cells.
School/Discipline
School of Biological Sciences
Dissertation Note
Thesis (Ph.D.) -- University of Adelaide, School of Biological Sciences, 2023
Provenance
This thesis is currently under embargo and not available.